Abstract
Prognostic value of FGF23 in end-stage renal disease (ESRD) patients is controversial. A systematic review was conducted to quantify the association between elevated FGF23 and overall mortality among ESRD patients. MEDLINE, EMBASE, PubMed and reference lists were searched. Quality of the included studies was evaluated using Newcastle-Ottawa Scale checklist. Pooled effects were calculated as hazard ratio using fixed-effect models, and chi-square test was used for heterogeneity testing. Seven studies (1406 patients) were included. Patients were at mean age of 62.3. Mean follow-up was 29.4 months. From the pooled analysis, elevated FGF23 was significantly associated with increased all-cause mortality (hazard ratio: 1.53; 95% CI: 1.05-2.25). p-value for heterogeneity was 0.10, I(2) = 48%. ESRD patients with elevated FGF23 concentration have higher risk of death.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
